Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance
Abstract Introduction In ORAL Surveillance, incidence rates (IRs) of major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer [NMSC]) in cardiovascular (CV)-risk-enriched patients with rheumatoid arthritis (RA) were numerically greater with tofacitinib in North...
Saved in:
Main Authors: | Bogdan Batko, Slawomir Jeka, Piotr Wiland, Agnieszka Zielińska, Maria Stopińska-Polaszewska, Marcin Stajszczyk, Magdalena Kosydar-Piechna, Mary Jane Cadatal, Jose L. Rivas |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2024-07-01
|
Series: | Rheumatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40744-024-00693-y |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01) -
Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
by: Małgorzata Wisłowska
Published: (2024-11-01) -
Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
by: Abhishek Zanwar, et al.
Published: (2017-01-01) -
Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India
by: Keerthi Talari, et al.
Published: (2021-01-01) -
Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
by: Richard Conway, et al.
Published: (2021-01-01)